Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary
Vanda Pharmaceuticals reported Q2 2026 drivers on its earnings call. Fanapt prescriptions rose 31% vs Q2 2025, while Hetlioz revenue fell 66% due to generic competition and a $7M shipment timing delay. Management cited higher operating expenses from four Phase 3 programs. It expects 2026 revenue growth of 23% at the midpoint, dependent on BYSANTI and NEREUS launch, and said cash should fund operations through end-2027.
How this was made
The 30-second read
Why it matters
The most tradable elements are the quantified prescription/revenue drivers, the explicit $7M shipment delay and NEREUS revenue constraint, and the dependence of 2026 revenue growth on BYSANTI launch success and NEREUS personal promotion starting later in 2026.
Market read
Traders can update expectations for 2H 2026 revenue trajectory based on quantified commercial momentum (Fanapt) versus erosion and timing effects (Hetlioz, NEREUS stocking/returns) and on the stated regulatory/launch calendar.
What to watch
The call emphasizes shipment timing and wholesaler stocking uncertainty; traders may underweight how these mechanics can swing quarterly revenue and cash burn before Phase 3 and launch manufacturing conclude.
Background
Vanda’s Q2 2026 earnings call summary covers commercial performance (Fanapt, Hetlioz, NEREUS), Phase 3 progress, and 2026 guidance assumptions plus regulatory timing.
Ticker impact
Vanda’s Q2 call highlights Fanapt prescription growth, Hetlioz revenue decline from generic competition, and 2026 guidance tied to BYSANTI and NEREUS promotion.
Moderate volatility likely around 2026 launch milestones and the December 2026 PDUFA/hearing catalysts, with downside risk if revenue recognition delays persist.
The article provides specific drivers (31% Fanapt prescription growth, Hetlioz down 66% with a $7M shipment delay, and 2026 revenue midpoint +23% dependent on BYSANTI and NEREUS promotion) plus concrete regulatory timing (December 2026 PDUFA for Imsidolimab, early 2027 ALJ recommendation).
Market effects
Reinforces the biopharma theme that commercial execution and revenue recognition timing can dominate near-term results even with clinical progress.
No clear regional spillover beyond US-listed specialty pharma sentiment.
Limited, as the catalysts described are US regulatory and US commercial execution.
Counterpoint
Fanapt growth may be partially offset by Hetlioz generic pressure and revenue recognition timing, so the +23% 2026 midpoint could be optimistic if launch ramp KPIs underperform.
Key entities
- companyVanda Pharmaceuticals Inc.
US-listed specialty pharma whose Q2 call provides quantified commercial drivers, 2026 guidance assumptions, and regulatory/clinical timing.
- productFanapt
Vanda’s antipsychotic; call cites 31% increase in total prescriptions vs Q2 2025 and 300% increase in new-to-brand prescriptions vs Q2 2024.
- productHetlioz
Vanda’s jet lag disorder therapy; call cites 66% revenue decline due to generic competition and a $7M shipment delay shifting recognition to Q3.
- productNEREUS
Vanda’s GLP-1 induced vomiting program; call cites DTC launch in May 2026, conservative revenue recognition, and a $12.6M revenue constraint tied to returns/demand uncertainty.
- productImsidolimab
Regulatory milestone referenced via a December 2026 PDUFA date assumption in 2026 guidance.
